New cholesterol drug candidate enters early human testing
NCT ID NCT07152873
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test a new drug formulation (AD-117) for mixed dyslipidemia, a condition involving high cholesterol and triglycerides. Sixty healthy adults will receive a single dose of either the new or a reference formulation to compare how the body processes each. The main goal is to check safety and drug levels in the blood, not yet to see if it treats the condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD-117 (a drug for mixed dyslipidemia)
What this could lead to
If successful, this could lead to a new treatment option for managing mixed dyslipidemia, a condition with high cholesterol and triglycerides.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only tests safety and drug processing, not whether the drug actually works for the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H Plus Yangji Hospital
Seoul, South Korea